ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 22 of 59
УЖМБС 2020, 5(5): 185–191
Clinical Medicine

Pathogenetic Changes in the Expression of Apoptotic Marker Caspase-3 in Patients with Type IІ Diabetes Mellitus and Excess Body Weight and Obesity

Solovyuk A. A.

The determination of molecular mechanisms, genetic control pathways, and modeling of apoptotic processes are necessary for understanding the pathogenesis of type 2 diabetes mellitus, especially in combination with obesity and excess body weight, which in the future may create prerequisites for the search for pathogenetic treatment. The purpose of the study was to assess the state of apoptosis processes in patients with type 2 diabetes mellitus in combination with excess body weight and obesity, depending on the clinical characteristics of the disease. Material and methods. 98 people with diabetes mellitus were examined. The first group consisted of 64 people with excess body weight and obesity (body mass index >25). The second group included 34 people with type 2 diabetes mellitus and normal body weight (body mass index ≤25). The control group consisted of 28 practically healthy individuals, who were comparable to the first and second groups by gender and age. Results and discussion. The presence of type 2 diabetes mellitus, excess body weight and obesity in patients led to increasing the level of the marker of apoptotic death of body cells – caspase-3 by 16.52%. Patients with glycated hemoglobin HbA1c more than 8% showed an increase in caspase-3 compared with patients with compensated diabetes mellitus; the difference was more pronounced in patients with excess body weight and obesity (19.13%, p <0.05). An increase in the duration of type 2 diabetes mellitus led to the activation of apoptosis processes, which was manifested in the rise of the studied apoptosis marker, caspase-3, both in patients with and without obesity (p <0.05). The development of the complication of type 2 diabetes mellitus in obese patients increased caspase-3 levels by 29.04% (p <0.05) in the absence of significant changes in this marker in patients with type 2 diabetes mellitus without obesity. Conclusion. The dynamics of apoptotic processes in patients with type 2 diabetes mellitus combined with and obesity, depending on the clinical characteristics of patients, is closely related to the level of apoptosis marker – caspase of the cysteine proteinase group – caspase-3

Keywords: apoptosis, metabolic syndrome, cysteine proteases, cardiovascular risk, compensation of diabetes mellitus

Full text: PDF (Ukr) 293K

  1. MacGregor C, Has P, Nardella D, Werner E. Comparing Glucose Challenge Test Screening Thresholds in Obese and Overweight Gravidas. Am J Perinatol. 2019 Sep 6.
  2. Gadelha AB, Neri SGR, Vainshelboim B, Ferreira AP, Lima RM. Dynapenic abdominal obesity and the incidence of falls in older women: a prospective study. Aging Clin Exp Res. 2019 Sep 5.
  3. Marcus MD. Obesity and eating disorders: Articles from the International Journal of Eating Disorders 2017-2018. Int J Eat Disord. 2018 Nov; 51(11): 1296-1299.
  4. Dai D, Mao Y, Jin H, Zhang W. Efficacy and hypoglycemic risk of sitagliptin in obese/overweight patients with type 2 diabetes compared with GLP-1 receptor agonists: A meta-analysis. Medicine (Baltimore). 2019 Sep; 98(36): e17081.
  5. Germain N, Khalfallah Y, Estour B, Galusca B. Insulin tolerance test predicts non response vs. sustained efficacy of Liraglutide on glycemic control in type 2 diabetes patients: A prospective real-world setting study. Diabetes Res Clin Pract. 2018 Mar; 137: 20-27.
  6. Ming-Yan Y, Jing Z, Shu-Qin G, Xiao-Liang B, Zhi-Hong L, Xue Z. Liraglutide inhibits the apoptosis of human nucleus pulposus cells induced by high glucose through PI3K/Akt/caspase-3 signaling pathway. Biosci Rep. 2019 Aug 19; 39(8): pii: BSR20190109.
  7. Liang M, Li A, Lou A. Advanced oxidation protein products promote NADPH oxidase-dependent β-cell destruction and dysfunction through the Bcl-2/Bax apoptotic pathway. Lab Invest. 2017 Jul; 97(7): 792-805.
  8. Tomita T. Apoptosis in pancreatic β-islet cells in Type 2 diabetes. Bosn J Basic Med Sci. 2016; 16(3): 162-179.
  9. Jeffery N, Harries LW. β-cell differentiation status in type 2 diabetes. Diabetes Obes Metab. 2016; 18(12): 1167-1175.
  10. Kaneko YK. Development and Analysis of Novel Therapeutic Targets to Improve Pancreatic β-Cell Function in Type 2 Diabetes]. Yakugaku Zasshi. 2016; 136(12): 1623-1629. [Japanese].
  11. Casella S, Bielli A, Mauriello A, Orlandi A. Molecular Pathways Regulating Macrovascular Pathology and Vascular Smooth Muscle Cells Phenotype in Type 2 Diabetes. Int J Mol Sci. 2015; 16(10): 24353-24368.
  12. Pandey VK, Mathur A, Kakkar P. Emerging role of Unfolded Protein Response (UPR) mediated proteotoxic apoptosis in diabetes. Life Sci. 2019; 216: 246-258.
  13. Berchtold LA, Prause M, Størling J, Mandrup-Poulsen T. Cytokines and Pancreatic β-Cell Apoptosis. Adv Clin Chem. 2016; 75: 99-158.
  14. Quan W, Jo EK, Lee MS. Role of pancreatic β-cell death and inflammation in diabetes. Diabetes Obes Metab. 2013; 15 (Suppl 3): 141-151.
  15. Majtnerová P, Roušar T. An overview of apoptosis assays detecting DNA fragmentation. Mol Biol Rep. 2018; 45(5): 1469-1478.
  16. Kalpage HA, Bazylianska V, Recanati MA, Fite A, Liu J, Wan J, et al. Tissue-specific regulation of cytochrome c by post-translational modifications: respiration, the mitochondrial membrane potential, ROS, and apoptosis. FASEB J. 2019; 33(2): 1540-1553.
  17. Ljubkovic M, Gressette M, Bulat C, Cavar M, Bakovic D, Fabijanic D, et al. Disturbed Fatty Acid Oxidation, Endoplasmic Reticulum Stress, and Apoptosis in Left Ventricle of Patients With Type 2 Diabetes. Diabetes. 2019; 68(10): 1924-1933.
  18. Sudo C, Ogawara H, Saleh AW, Nishimoto N, Utsugi T, Ooyama Y, et al. Clinical significance of neutrophil apoptosis in peripheral blood of patients with type 2 diabetes mellitus. Lab Hematol. 2007; 13(3): 108-112.